

## Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry

This is the peer reviewed version of the following article:

*Original:*

Levy, R., Gérard, L., Kuemmerle Deschner, J., Lachmann, H.J., Koné Paut, I., Cantarini, L., et al. (2015). Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. ANNALS OF THE RHEUMATIC DISEASES, 74(11), 2043-2049 [10.1136/annrheumdis-2013-204991].

*Availability:*

This version is available <http://hdl.handle.net/11365/976415> since 2016-11-20T10:23:19Z

*Published:*

DOI: <http://doi.org/10.1136/annrheumdis-2013-204991>

*Terms of use:*

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

## Phenotype and genotype of Cryopyrine Associated Periodic syndrome (CAPS) : a series of 136 patients from the Eurofever international registry

R. Levy<sup>1</sup>, L. Gérard<sup>2</sup>, J. Kuemmerle-Deschner<sup>3</sup>, H.J. Lachmann<sup>4</sup>, I. Koné-Paut<sup>5</sup>, L. Cantarini<sup>6</sup>, P. Woo<sup>7</sup>, A. Naselli<sup>8</sup>, B. Bader-Meunier<sup>1</sup>, A. Insalaco<sup>9</sup>, S. M. Al-Mayouf<sup>10</sup>, S. Ozen<sup>11</sup>, M. Hofer<sup>12</sup>, J. Frenkel<sup>13</sup>, C. Modesto<sup>14</sup>, I. Nikishina<sup>15</sup>, T. Schwarz<sup>16</sup>, S. Martino<sup>17</sup>, A. Meini<sup>18</sup>, A. Martini<sup>8, 19</sup>, N. Ruperto<sup>8</sup>, B. Neven<sup>1\*</sup>, and M. Gattorno<sup>8\*</sup> for PRINTO and Eurofever.

<sup>1</sup> Université Paris-Descartes, Hôpital Necker-Enfants Malades. Centre de référence national pour les Arthrites Juveniles, Unité d'Immunologie, Hématologie et Rhumatologie Pédiatrique, Paris, France

<sup>2</sup> saint louis (please provide complete affiliation)

<sup>3</sup> Universitätsklinik für Kinderheilkunde und Jugendmedizin, Tübingen, Germany

<sup>4</sup> National Amyloidosis Centre, ~~Royal Free Campus~~, University College London Medical School, Royal Free Campus, London, United Kingdom

<sup>5</sup> Centre de référence national des maladies auto-inflammatoires, CEREMAI, rhumatologie pédiatrique, CHU Le Kremlin Bicêtre (University of Paris SUD), Le Kremlin Bicêtre (Paris), France

<sup>6</sup> Rheumatology Unit, Policlinico le Scotte, University of Siena, Siena, Italy

<sup>7</sup> Center of Paediatric and Adolescent Rheumatology - UCL, Great Ormond Street, London, UK

<sup>8</sup> Istituto G. Gaslini, UO Pediatria II – Reumatologia

<sup>9</sup> Reumatologia, Ospedale Pediatrico Bambin Gesù, Roma, Italy

<sup>10</sup> Department of Pediatric, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

<sup>11</sup> Department of Pediatric Nephrology and Rheumatology, Hacettepe University, Ankara, Turkey

<sup>12</sup> Pédiatrie, Centre Multisite Romand de Rhumatologie Pédiatrique / Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

<sup>13</sup> Department of Paediatrics, University Medical Center Utrecht, Utrecht, Netherlands

<sup>14</sup> Reumatologia, Hospital Valle de Hebron, Barcelona, Spain

<sup>15</sup> Children's Department, Institute of Rheumatology RAMS, Moscow, Russian Federation

<sup>16</sup> Section Pediatric Rheumatology and Osteology, University School of Medicine Children's Hospital, Wuerzburg, Germany

<sup>17</sup> Dip.to di Scienze Pediatriche e dell'Adolescenza, Clinica Pediatrica Università di Torino, Italy

<sup>18</sup> Dipartimento di Pediatria, Unità di Immunologia e Reumatologia Pediatrica, Clinica Pediatrica dell'Università di Brescia, Spedali Civili, Brescia, Italy

<sup>19</sup> Department of Pediatrics, University of Genoa, Italy

\*these authors contributed equally to this work

Corresponding authors :

bénédicte NEVEN

149 rue de Sèvres

75015 PARIS

+33/ 1 44 49 48 22

benedicte.neven@nck.aphp.fr

text count : 3181 words (max 3000)

## ABSTRACT

**Objective:** ~~to~~ To evaluate genetic, demographic and clinical features in patients with cryopyrin-associated periodic syndrome (CAPS) from the Eurofever registry. To evaluate genotype-phenotype correlation and define predictive markers of disease-severity.

**Methods:** A web-based registry collected retrospective data on patients with CAPS. Experts in the disease independently validated cases. Patients carrying *NLRP3* variants and germline mutation-negative patients (with complete gene screening) were included.

**Results:** 136 patients were analysed. Median age at disease onset was 9 months; median duration of follow-up was 15 years. Skin rash, articular involvement and fever were the most prevalent features; neurological involvement including severe complications were noticed in 40% and 12% respectively; ophthalmological involvement was observed in 71% and neurosensory hearing loss in 42%. 133 patients carried heterozygous germline mutation while 3 patients were mutation negative. Thirty-one different *NLRP3* mutations were recorded, ~~including 7 recurrent~~ mutations ~~accounting~~ accounted for 78% of the patients while 24 rare variants were reported in 27 cases. The later variants were significantly associated with early disease onset, neurological complications (including severe ones) and severe articular involvement. T348M variant was associated with disease onset before 6 months, a chronic course and hearing loss. Neurological involvement was significantly less associated with V198M, E311K and A439V alleles. Early onset was ~~predictable~~ predictive of severe neurological complications and hearing loss.

**Conclusion:** Patients carrying rare *NLRP3* variants are at risk of severe disease; ~~early-onset~~ <onset before 6 months ~~exposes to~~ is associated with an increase in neurological involvement and neurosensory hearing loss. These findings may impact on treatment decisions.

## INTRODUCTION :

The cryopyrin-associated periodic syndromes (CAPS) belong to the growing family of inherited autoinflammatory syndromes characterised by recurrent bouts of systemic and organ specific inflammation related to inappropriate activity or regulation of the innate immune system. CAPS are usually dominantly inherited but *de novo* cases are also reported. They encompass ~~3~~three distinct diseases with a continuum of severity from the mildest, familial cold autoinflammatory syndrome (FCAS, OMIM 120100), to the most severe, neonatal-onset multisystem inflammatory disease (NOMID) [or chronic infantile neurologic cutaneous articular (CINCA) syndrome, OMIM 607115], while patients with Muckle-Wells syndrome (MWS, OMIM 191900) have an intermediate phenotype. Patients with FCAS are characterised by recurrent cold-induced episodes of fever, urticaria-like rash, arthralgia and ~~conjonetivitis~~conjunctivitis; in MWS, the disease-pattern is more chronic than recurrent, patients often complain of fever, rash and arthritis or arthralgia without specific triggers, sensorineural hearing loss and AA amyloidosis can developed in adulthood<sup>1</sup>; CINCA/NOMID patients present with unconstant fever, urticaria-like rash and neurosensorial involvement characterised by chronic aseptic meningitis, ~~papillary oedema~~papilloedema, papillitis and deafness. Hypertrophic arthropathy with contractures and bone deformity can occur in severely affected patients. Early onset is frequently but not exclusively reported in CINCA, but not exclusively<sup>2, 3</sup>.

CAPS are ~~genetically related to~~caused by dominantly ~~inherited~~inherited or *de novo* gain of function mutations of NLRP3 (nucleotide-binding domain, leucine-rich repeat family, pyrin domain containing 3)<sup>4-6</sup>. Somatic mutations have been recently described in CINCA/NOMID germline mutation-negative patients<sup>7,8, 9</sup>. ~~This NLRP3 gene encodes for a protein, called~~ cryopyrin, a key component of the inflammasome. This multimeric cytosolic protein complex ~~triggers~~controls activation of caspase-1, which in turns catalyses the cleavage of pro-interleukin-1 $\beta$  (IL-1) into IL-1 $\beta$ , a potent pro-inflammatory cytokine<sup>10</sup>. Most of the recognised NLRP3 variants ~~described today~~ are missense mutations found in exon 3 that encode for the nucleotide-binding domain of cryopyrin<sup>11</sup>. ~~Very A~~ few mutations ~~were have been~~ found in exons 4, 6 and 8 encoding ~~for~~ the leucine-rich-repeat domain<sup>12</sup>. NLRP3 mutations are associated with constitutive activation of the inflammasome ~~with and~~ overexpression of IL-1 $\beta$ . The better understanding of both the genetic basis and physiopathology of CAPS, underlines the major role of IL-1 $\beta$ , ~~offer new~~and the potential of targeted therapeutics, ~~perspectives. In fact i~~ inhibition of IL-1 $\beta$  ~~in CAPS~~has dramatically improved all clinical

Formattato: Tipo di carattere: Corsivo

Commentato [HJL1]: This doesn't really work in English - do you mean intermittent or episodic?

Commentato [HJL2]: This isn't clear - Variable, intermittent, persistent

Formattato: Evidenziato

Formattato: Evidenziato

Formattato: Allineato al centro

Formattato: Tipo di carattere: Corsivo

Formattato: Tipo di carattere: Corsivo

Formattato: Tipo di carattere: Corsivo

Formattato: Inglese (Regno Unito)

manifestations related to inflammation<sup>13</sup>, but treatments are very costly and decisions around timing of treatment initiation in young children can be complex particularly as prediction of the course of the disease and the risk of long-term organ damage remains extremely challenging.-

Formattato: Inglese (Regno Unito)

Formattato: Inglese (Regno Unito)

~~Thanks to the EUROFEVER registry, an international survey of autoinflammatory diseases~~ We undertook a detailed phenotype and genotype description of a large international cohort of CAPS patient enrolled in the EUROFEVER registry, an international survey of autoinflammatory diseases and s. ~~We~~ searched for genetic and phenotypic predictive markers of a more severe outcome.

## PATIENTS AND METHODS :

### Patients and study design

All patient data were extracted from The EUROFEVER registry. This international survey of autoinflammatory diseases<sup>17</sup> has been enrolling patients suffering from various autoinflammatory syndromes including Cryopyrin-associated periodic syndromes (CAPS) since November 2009. This Project was sponsored by the Autoinflammatory Diseases' Working Group of the Paediatric Rheumatology European Society (PRES) and supported by the Executive Agency For Health and Consumers (EAHC, Project No 2007332, <http://ec.europa.eu/eahc/projects/database.html>)

Ethical committee approval for entering patients in the registry was obtained in the participating countries according to local regulatory requirements.

Patients with diagnosis of CAPS (as validated by experts BN, JKD and MG) and carrying germline *NLRP3* mutation or without germline mutation despite complete screening of the gene were included in this study. Demographic data, clinical manifestations, laboratory findings, data from other diagnostic procedures and information about molecular genetic variants were collected anonymously. The database cut-off for analysis was June 2012.

Commentato [HJL3]: see HJLcomment4

Commentato [HJL4]: Really? Ours had exons 3, 4 and 6 as a maximum

### Phenotype and genotype characterization:

Detailed epidemiological and demographic data were collected. The clinical characteristics were also recorded including: disease pattern defined by either recurrent acute episodes, chronic disease or chronic with acute exacerbations; constitutional symptoms including fever, fatigue, malaise, mood disorders or failure to thrive; cutaneous involvement and detailed characteristics of skin rash. Organ specific involvement ~~was arbitrarily classified as were~~

~~divided into~~ mild or severe ~~groups~~. ~~Mild~~ musculo-skeletal manifestations were ~~considered in~~ ~~included~~ ~~of~~ myalgia ~~and or~~ arthralgia; severe musculo-skeletal manifestations encompassed: overgrowth, joint contractures, bone deformity, bone erosion or osteolytic lesions. Mild neurological involvement was defined by the presence of morning headache, papilloedema or aseptic meningitis; while the presence of epilepsy, hydrocephalus or mental retardation ~~items~~ classified as severe. Mild ocular manifestations were defined by conjunctivitis or uveitis while severe ocular involvement ~~was defined by~~ ~~included~~: optic nerve atrophy, cataract, impaired vision. Neurosensorial hearing loss was based on the result of at least one pathologic audiogram.

The most relevant and well documented clinical characteristics were grouped into ~~9~~ nine main items: age of onset before 6 months, chronic disease course, positive familial history, cold trigger, mild neurological involvement, severe neurological involvement, mild articular involvement, severe articular involvement, hearing loss.

~~Germline sequencing of NLRP3 gene was performed and documented in all patients. Informations about sequencing were also collected.~~

#### Statistical analysis:

Descriptive statistics were reported as medians with interquartile range (IQR) values, or numbers with percentage (%). To test the association between the main clinical phenotypes and genotype pattern, nine genotype subgroups were defined. Seven subgroups were defined with patients bearing one of the most frequent mutations (~~occurring for~~ found in  $\geq 5$  unrelated patients): R260W, E311K, V198M, T348M, D303N, Q703K, A439V. Patients with rare mutations ( $\leq 2$  unrelated patients) were pooled in a separate group, and patients with no mutation accounted for the last group. Clinical characteristics of the patients were compared on the basis of the presence or not of each mutation. Univariate association between each of the main clinical characteristics was conducted in a secondary analysis. Comparison between groups was performed using of the Fisher's exact test and the chi-squared test, when appropriate. All tests were two-sided. The Benjamini-Hochberg procedure was used to correct for multiple comparisons, and  $p < 0.01$  was considered significant. All analyses were conducted using Stata, version 11.0 (StatCorp Inc., College Station, TX, USA)

**Commentato [HJL5]:** I have reservations about this. 5 of these are clear cut mutations which have been previously described, V198M is difficult - again with a literature discussing that it is a common variant and can be disease causing in a minority and Q703K is really contentious and is very common in healthy Caucasians. I think this needs to be clearly discussed in the introduction and a justification for lumping them together put in here. Without that it reads as if equal weight is given to all these sequence variants and I think that just isn't true. Given the difficulties here I also think the phenotype of the excluded patients and the role of the validating clinicians has to be expanded upon - there needs to be a clear description of why the Q703K patients in particular were included in the cohort.

**Formattato:** Evidenziato

## RESULTS:

#### Demographic data:

In June 2012, 157 patients were available in the registry, 9 patients were excluded during the validation process and 12 patients were excluded because of absence of genetic screening (n=10) or because of incomplete screening of the gene in mutation negative patients (n=2). A total of 136 patients (67 female, 69 male) were analyzed and were enrolled by 27 centers from 16 countries: United Kingdom (49), France (29), Italy (28), Germany (10), Netherlands (4), Spain (4), India (2), Switzerland (1), Turkey (1), Russia (2), Pakistan (1), Australia (1), South Africa (1), Saudi Arabia (1), Chile (1), and Denmark (1). One hundred and twenty nine patients were Caucasian, 7 were Asian. A positive familial history was reported in 66 patients while 54 cases were sporadic (status unknown for 6).

Demographic data are summarized in table 1. Median age at disease onset and at disease diagnosis was respectively 9 months (IQR, 44 days to 5 years) and 15 years (IQR, 5 to 36 years). The median age at last visit was 15 years (IQR, 8 to 35 years).

#### Clinical characteristics:

Clinical characteristics of the patients are detailed in table-Table 2. Seventy-eight patients (57%) had a chronic course while 58 (43%) experienced only acute episodes. Skin rash, articular involvement and fever were the most prevalent features, observed respectively in 97%, 86% and 84%. Six patients (4%) suffered from severe articular involvement as previously defined: flexion contractures (n = 3), patella overgrowth (n = 1), bone deformity (n = 4), bone erosions (n = 1), or osteolytic lesions (n = 2). Neurological involvement was noticed in 55 patients (40%) including 16 individuals with severe neurological involvement (seizures (n = 2), hydrocephalus (n = 10), mental retardation (n= 9)). Ophthalmological involvement was observed in 71%. Severe ophthalmological involvement was documented in 16 patients (12%) (Optic nerve atrophy (n = 6), cataract (n = 4), glaucoma (n = 2), or impaired vision (n = 8)). Neurosensory hearing loss was reported in 42% documented by an audiogram in all cases. AA amyloidosis was identified in 5 patients carrying R260W (3 patients) V198M (1 patient) and A439V (1 patient) mutations at a median age of 29 years old (range 21 to 52 years). Ninety-five patients (70%) suffered from various constitutional symptoms. A total of 83 patients suffered from recurrent episodes. Characteristics of these bouts are given in table-Table 3. Overall, 77% of patients received anti-IL-1 drugs during the course of the disease, anakinra or canakinumab (figure 2 b).

**Commentato [HJL6]:** Probably needs some clinical details here

**Commentato [HJL7]:** This could really do with defining - perhaps something along the lines of 'symptoms almost every day'.

**Commentato [HJL8]:** Not sure what this means - in relation to chronic disease course or acute attacks

#### Genotypic characterization:

Heterozygous germline mutation was reported in 133 patients. ~~Of the while 3 three~~ patients ~~without did not carried~~ germline mutations ~~t. In the later, 2 two patients turned out were~~ subsequently found to carry ~~a~~ somatic *NLRP3* mutations. Sequencing of the whole gene was performed in 13 patients (10%) while most relevant exons were sequenced in 93 cases (68%) and most relevant point mutations searched in 9 (7%) cases (information on *NLRP3* sequencing exhaustivity was not available in 21 cases (15%)). Thirty-one germline ~~different~~ *NLRP3* mutations were ~~recorded and showed detected (in F~~ Figure 1b). Seven mutations ~~were recurrent and occurred were found~~ in 106 (78%) patients, including 5 patients ~~with both carrying both the variants~~ R260W and V198M variants. Twenty-seven patients (20%) carried other rare mutations (Figure 1a.) including ~~2 two previously~~ unreported *NLRP3* variants (I572S, L1016F). ~~A non recurrent Twenty-one mutations was were found in a single individual reported in 21 cases, 3 three~~ mutations (M662T, P350M and I572F) were ~~documented each found~~ in ~~2 two~~ unrelated patients ~~each~~. All mutations were nonsense. All except ~~ed one (L1061F )~~ were located in *NLRP3* exon 3.

Formattato: Tipo di carattere: Corsivo

#### Association between genotype and clinical characteristics:

Distribution of the clinical characteristics in each of the genotypes subgroups is detailed in ~~table-Table~~ 4, illustrating positive or negative significant associations between each clinical item and a specific genotype. The R260W variant was associated with ~~the presence of a~~ cold triggered ~~symptomsing~~ ( $p < 10^{-3}$ ), a positive familial history ( $p < 10^{-3}$ ) and a trend to ~~a~~ delayed age at symptom onset after 6 months ( $p = 0.04$ ). The T348M variant was associated with ~~an early~~ disease onset before 6 months ( $p = 0.01$ ), a chronic course ( $p = 0.007$ ) and ~~a~~ frequent hearing loss ( $p = 0.01$ ). V198M, E311K and A439V alleles were rarely associated with neurological involvement. Finally, young age at onset ( $p = 0.003$ ); neurological manifestations ( $p = 0.008$ ) including severe ones ( $p < 10^{-3}$ ); severe articular involvement ( $p = 0.01$ ) and sporadic pattern ( $p < 10^{-3}$ ) were significantly commoner in associated with patients bearing a rare mutation. In this later group, we found a trend for a higher risk ~~for of~~ neurosensorial hearing loss ( $p = 0.02$ ). Distribution of the main clinical features in patients carrying rare variants is reported in supplementary Table 1.

Percentage of patients treated by anti-IL1 drugs in each genotype group is given in Ffigure 2b. Lower ~~erest rates~~ of treatment ~~was were~~ observed in patients carrying Q703K (11%), V198M (60%) and R260W (70%) mutations.



#### Association among clinical manifestations:

Univariate associations between each of the main clinical phenotypes were tested in the entire cohort. A chronic disease course was more frequently observed in patients with disease onset before the age of 6 months compared to patients with later onset ( $p = 2.10^{-3}$ ). Early onset was also ~~predictable for~~ predictive of severe neurological complications ( $p < 10^{-3}$ ) and hearing loss ( $p = 0.01$ ). Patients with a positive familial history developed less severe disease compared to patients without, ~~by means of a~~ specifically with a lower risk for severe articular involvement ( $p = 0.01$ ), and both mild and severe neurological involvement ( $p = 10^{-3}$  and  $p < 10^{-3}$ , respectively). A cold trigger was more frequently identified in patients with familial history of CAPS ( $p < 10^{-3}$ ) and less frequently in patients with a chronic course of disease ( $p < 10^{-3}$ ). Finally, neurological involvement was frequently associated with hearing loss ( $p < 10^{-3}$ ). The other clinical phenotypes ~~were not associated~~ showed no associations with ~~to~~ each other.

#### **DISCUSSION:**

The present work provides a detailed description of clinical and genotype features of the largest series yet of patients suffering from cryopyrin-associated periodic syndromes (CAPS). There were collected via the EUROFEVER registry, designed to set up an international web based registry of autoinflammatory diseases. This large collection of data allowed statistically and clinically meaningful analysis of phenotype/genotype correlations and identified risk factors of severe disease. It also highlights the very wide spectrum of these diseases. Importantly, patients with rare mutations were found to have a more severe phenotype. An early disease onset before the age of 6 months was predictive of a more severe outcome.

~~Because of~~ As the phenotypes overlapping phenotypes, the older subdivisions of strict definitions of CAPS syndromes into so-called FCAS, MWS or CINCA were felt to be inappropriate and not applied ~~to-in~~ this study. Instead, ~~relevant~~ clinical symptoms were used each type of involvement. In many respects, our data confirm clinical descriptions from earlier publications<sup>18,19,20</sup>. Disease course was prevalently dominantly chronic. R ~~Skin-rash~~ frequent clinical manifestation, being present in 97% of patients. ~~Skin-r~~ Rash was ~~not~~ patients and classical urticarial rash was reported in only 89% of patients. ~~Disease course was~~ involvement as defined by presence of at least one of: morning headache, and/or chronic or and/or papillary oedema was identified in 40% of patients. Because documentation of CSF examination and fundoscopy were not exhaustive (in only 64% and 79% of patients respectively) we ~~can not~~ cannot exclude ~~miss-estimation~~ underestimation of neurological

involvement. However, morning headaches ~~were have been reported to be~~ highly predictive chronic meningitis ~~in earlier studies in CAPS as previously reported<sup>21</sup> as meningitis was~~ arthropathy) ~~noticed in six~~ 6 patients was less frequently reported than in previous series<sup>6,16,20</sup>. amyloidosis was ~~rare and~~ reported in ~~5-five~~ 5 patients ~~only~~. This AA amyloidosis is known to ~~onset~~ complication (median age of onset of 31 years<sup>22</sup>) ~~is rare and its rarity~~ compared to reports (~~where it developed in~~ up to 10%)<sup>22</sup>. ~~This~~ might be related to the ~~relative~~ young cohort (18 years) or ~~to early introduction of~~ therapeutic interventions that ~~prevent chronic inflammation~~ impact on this severe complication.

We detected a total of 31 missense mutations including ~~2-two~~ 2 previously unreported mutations. Distribution of the *NLRP3* variants documented in this study was very similar to previous studies; the frequent *NLRP3* mutations: R260W<sub>Δ</sub>, T348M<sub>Δ</sub>, V198M<sub>Δ</sub>, A439V<sub>Δ</sub>, D303N<sub>Δ</sub>, Q703K and E311K accounted for 71% of patients in our cohort and rare variants accounted for 20%. This distribution is very similar to Cuisset and al<sup>11</sup>. Surprisingly, only ~~3~~ ~~three~~ 3 patients with typical severe CAPS phenotype were screened without any germline mutation ~~which is much~~ ~~It's~~ less ~~common~~ than previously reported<sup>69</sup>.

Since the discovery of the gene responsible for FCAS, MWS and CINCA/NOMID<sup>4</sup>, and the understanding of their common molecular basis, some degree of genotype/phenotype correlation has been raised by several studies, even though phenotypic variability was also noticed<sup>14,6,15,16</sup>, suggesting ~~the possible~~ role ~~for~~ additional genetic and environmental factors. Assessment of genotype/phenotype correlations is difficult and can be limited by several factors. In CAPS

~~The~~ ~~We found the~~ T348M mutation was significantly associated with early onset, a chronic course and a frequent hearing loss. These findings are in accordance with previous reports<sup>12, 14, 15, 29-31</sup>. R260W was the most frequently identified variant in 36 patients of our cohort, with age at last visit of 32.2 years. It is the most frequently reported mutation in the literature and was found associated with FCAS, MWS or atypical autoinflammatory syndrome<sup>32,14,11</sup>. In our cohort, this variant was significantly associated with presence of a cold trigger and an autosomal dominant pattern of inheritance. There was a trend for a later onset and a recurrent pattern of evolution. A439V has been previously reported in patients with mild phenotype, FCAS or MWS<sup>4</sup>. In our study, ~~the among~~ 14 patients with a median age of 51 years old at last visit, hearing loss and neurological involvement ~~developed significantly less frequently~~ ~~was significantly less frequent~~ (identified in one patient each), while autosomal dominant pattern of inheritance was the rule. Interestingly, patients with E311K displayed a high rate of hearing loss, as previously reported<sup>33</sup>.

Even though D303N variant and germline mutation negative CAPS ~~effectives~~ were too ~~low to~~ statistically ~~ly~~ significance analysis, they were associated with severe phenotype as previously reported<sup>5, 14, 16, 34, 35,29,12</sup>.

The *NLRP3* V198M and Q703K alleles deserve special comments. They are both found in healthy Caucasian controls (with alleles frequencies of 0.7 and 5% respectively ref 16) and are considered as low penetrant variants associated with mild disease<sup>16, 32, 36</sup> also Rowczenio DM, Arthritis Res Ther. 2013 Feb 19;15(1):R30. They were identified in 12 and 9 patients of this cohort respectively and were associated with a mild phenotype. Neurological involvement and hearing loss were rarely described despite long follow-up. In addition, 5 patients were reported with both V198M and R260W, these patients did not differ in phenotype and severity.

~~Because of the~~The retrospective design of this work produces a number of limitations ~~should also be discussed~~. Some data were missing and patients ~~were heterogeneously~~ documentation was heterogeneous. Details about treatment were incomplete ~~for in~~ some patients. In addition, the fact that a very large number of centers and clinicians included small numbers of patients each, may introduce bias of data interpretation.

In conclusion, we provide a detailed description of both clinical and genetic features of patient with CAPS in a large cohort of patients and have shown associations between genotype and phenotypic severity although the significance of common population variants such as Q703K still remains unclear.—This study highlights new insights ~~on in~~ CAPS that may help in every day clinical practice. While it remains challenging ~~to appreciate the outcome and to~~ anticipate potential complications, we suggest that sporadic cases, starting at an early age are at risk of severe neurological complications, and neurosensorial hearing loss especially in patients carrying rare germline *NLRP3* variants, T348M, D303N or somatic *NLRP3* mutation. These patients should be ~~investigated and~~ monitored closely and treatment should be discussed early to prevent long-term complications. In contrast, an autosomal dominant pattern of inheritance and a cold triggering seem to predict a better outcome with a ~~decrease lower~~ risk of severe organ damage.

**Commentato [HJL10]:** the largest and most recent series

**Commentato [HJL11]:** to patients with R260W or V198M?

**Commentato [HJL12]:** This needs expanding. There is a literature describing V198M and clearly in some individuals it is sufficient to cause classical CAPS and in other to cause other autoinflammatory symptoms. The role of Q703K is very much less clear - it is very frequent in Caucasian alleles - it is not at all clear that it is pathogenic - and it may be that it's finding here is incidental reflecting extensive genetic sequencing in patients with symptoms of unknown aetiology. I really think you need to expand on the Q703K clinical phenotype here - it is very soft indeed with no FH, later onset and no deafness.

## Bibliography

1. Muckle TJ. The 'Muckle-Wells' syndrome. *Br J Dermatol*. 1979; **100**(1): 87-92.
2. Prieur AM, Griscelli C. [Chronic meningo-cutaneo-articular syndrome in children]. *Rev Rhum Mal Osteoartic*. 1980; **47**(11): 645-9.
3. Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. *J Allergy Clin Immunol*. 2001; **108**(4): 615-20.
4. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. *Nat Genet*. 2001; **29**(3): 301-5.
5. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. *Am J Hum Genet*. 2002; **71**(1): 198-203.
6. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. *Arthritis Rheum*. 2002; **46**(12): 3340-8.
7. Saito M, Nishikomori R, Kambe N, Fujisawa A, Tanizaki H, Takeichi K, et al. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. *Blood*. 2008; **111**(4): 2132-41.
8. Arostegui JJ, Lopez Saldana MD, Pascal M, Clemente D, Aymerich M, Balaguer F, et al. A somatic NLRP3 mutation as a cause of a sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatal-onset multisystem inflammatory disease: Novel evidence of the role of low-level mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseases. *Arthritis Rheum*. 2010; **62**(4): 1158-66.9. Tanaka N, Izawa K, Saito MK, Sakuma M, Oshima K, Ohara O, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. *Arthritis Rheum*. 2011; **63**(11): 3625-32.
10. Masters SL, Lobito AA, Chae J, Kastner DL. Recent advances in the molecular pathogenesis of hereditary recurrent fevers. *Curr Opin Allergy Clin Immunol*. 2006; **6**(6): 428-33.
11. Cuisset L, Jeru I, Dumont B, Fabre A, Cochet E, Le Bozec J, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. *Ann Rheum Dis*. 2011; **70**(3): 495-9.
12. <http://fmf.igh.cnrs.fr/infevers>; IdU.
13. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. *Arthritis Rheum*. 2008; **58**(8): 2432-42.
14. Dode C, Le Du N, Cuisset L, Letourneur F, Berthelot JM, Vaudour G, et al. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. *Am J Hum Genet*. 2002; **70**(6): 1498-506.

15. Neven B, Callebaut I, Prieur AM, Feldmann J, Bodemer C, Lepore L, et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. *Blood*. 2004; **103**(7): 2809-15.
16. Aksentijevich I, C DP, Remmers EF, Mueller JL, Le J, Kolodner RD, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. *Arthritis Rheum*. 2007; **56**(4): 1273-85.
17. Toplak N, Frenkel J, Ozen S, Lachmann HJ, Woo P, Kone-Paut I, et al. An International registry on Autoinflammatory diseases: the Eurofever experience. *Ann Rheum Dis*. 2012.
18. Cuisset L, Drenth JP, Berthelot JM, Meyrier A, Vaudour G, Watts RA, et al. Genetic linkage of the Muckle-Wells syndrome to chromosome 1q44. *Am J Hum Genet*. 1999; **65**(4): 1054-9.
19. Muckle TJ WM. Urticaria, deafness and amyloidosis: A new heredo-familial syndrome *Journal of medicine* 1962; **122**: 235-48.
20. Prieur AM, Griscelli C, Lampert F, Truckenbrodt H, Guggenheim MA, Lovell DJ, et al. A chronic, infantile, neurologic, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. *Scand J Rheumatol Suppl*. 1987; **66**: 57-68.
21. Kitley JL, Lachmann HJ, Pinto A, Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. *Neurology*. 2010; **74**(16): 1267-70.
22. Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL, et al. AA amyloidosis complicating the hereditary periodic fever syndromes. *Arthritis Rheum*. 2013; **65**(4): 1116-21.
23. Matsubara T, Hasegawa M, Shiraishi M, Hoffman HM, Ichiyama T, Tanaka T, et al. A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents. *Arthritis Rheum*. 2006; **54**(7): 2314-20.
24. Caroli F, Pontillo A, D'Osualdo A, Travan L, Ceccherini I, Crovella S, et al. Clinical and genetic characterization of Italian patients affected by CINCA syndrome. *Rheumatology (Oxford)*. 2007; **46**(3): 473-8.
25. Lainka E, Neudorf U, Lohse P, Timmann C, Bielak M, Stojanov S, et al. Analysis of cryopyrin-associated periodic syndromes (CAPS) in German children: epidemiological, clinical and genetic characteristics. *Klin Padiatr*. 2010; **222**(6): 356-61.
26. Jesus AA, Silva CA, Segundo GR, Aksentijevich I, Fujihira E, Watanabe M, et al. Phenotype-genotype analysis of cryopyrin-associated periodic syndromes (CAPS): description of a rare non-exon 3 and a novel CIAS1 missense mutation. *J Clin Immunol*. 2008; **28**(2): 134-8.
27. Stojanov S, Weiss M, Lohse P, Belohradsky BH. A novel CIAS1 mutation and plasma/cerebrospinal fluid cytokine profile in a German patient with neonatal-onset multisystem inflammatory disease responsive to methotrexate therapy. *Pediatrics*. 2004; **114**(1): e124-7.
28. Canoui E, Maigne G, Jeru I, Amselem S, Kone-Paut I, Lambotte O. Atypical presentation of a cryopyrin-associated periodic syndrome, revealing a novel NLRP3 mutation. *Clin Immunol*. 2013; **148**(2): 299-300.
29. Arostegui JL, Aldea A, Modesto C, Rua MJ, Arguelles F, Gonzalez-Ensenat MA, et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. *Arthritis Rheum*. 2004; **50**(12): 4045-50.

30. Rosen-Wolff A, Quietzsch J, Schroder H, Lehmann R, Gahr M, Roesler J. Two German CINCA (NOMID) patients with different clinical severity and response to anti-inflammatory treatment. *Eur J Haematol.* 2003; **71**(3): 215-9.
31. Seitz M, Kamgang RK, Simon HU, Villiger PM. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome. *Ann Rheum Dis.* 2005; **64**(12): 1802-3.
32. Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. *Arthritis Rheum.* 2002; **46**(9): 2445-52.
33. Kuemmerle-Deschner JB, Lohse P, Koetter I, Dannecker GE, Reess F, Ummenhofer K, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome--description of a heterogeneous phenotype and response to treatment. *Arthritis Res Ther.* 2011; **13**(6): R196.
34. Granel B, Philip N, Serratrice J, Ene N, Grateau G, Dode C, et al. CIAS1 mutation in a patient with overlap between Muckle-Wells and chronic infantile neurological cutaneous and articular syndromes. *Dermatology.* 2003; **206**(3): 257-9.
35. Janssen R, Verhard E, Lankester A, Ten Cate R, van Dissel JT. Enhanced interleukin-1beta and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. *Arthritis Rheum.* 2004; **50**(10): 3329-33.
36. Porksen G, Lohse P, Rosen-Wolff A, Heyden S, Forster T, Wendisch J, et al. Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome. *Eur J Haematol.* 2004; **73**(2): 123-7.

## Legends of figures

### Figure 1: distribution of genotype among CAPS patients

- (a.) Distribution of NLRP3 mutations in the cohort of 136 patients and (b.) representation along crypyrin protein. Mutation in bold are the frequent one's. Mutations in gray belong to the group of rare mutations, mutations underlined were identified in two unrelated patients of the cohort.

### Figure 2: distribution of age at last visit and treatment according to the genotype

- (a.) Age at onset of the disease for the whole cohort and for each genotype subgroups. Median values are represented with horizontal bars.
- (b.) Percentage of patients treated with anti-IL-1 drugs for the whole cohort and for each genotype groups.
- (c.) Age at last visit for the whole cohort and for each genotype subgroups. Median values are represented with horizontal bars.

Table 1: characteristics of CAPS patients

	n (%)
Sex	
Male	69 (50)
Female	67 (50)
Sex ratio	1
Origin	
Caucasian	128 (94)
Asian	7 (5)
Other	1 (1)
Mode of inheritance	
AD	76 (58.5)
De novo	54 (41.5)
	Median (IQ25-75)
Age onset (years)	0,8 (0,1-5)
Age diagnosis (years)	15 (5-36)
Age at last visit (years)	15 (8-35)

IQ denotes inter-quartile

Commentato [HJL13]: Unless family screening has been performed you don't know that. This is particularly true for the more difficult variants V198M, Q703K etc. It might be better to say No Family History

Formattato: Tipo di carattere: Corsivo

Formattato: Tipo di carattere: Corsivo



**Table 2: clinical characteristics**

	<b>n</b>	<b>%</b>
Fever	108	84
Disease Pattern		
Recurrent	58	43
Chronic with <del>recurrent</del> <u>exacerbations</u>	25	18
Chronic	53	39
Constitutional Symptoms	95	70
Skin Involvement	132	97
Urticarial rash	121	89
Maculo-papular rash	36	26
Articular Involvement	117	86
Myalgia	60	44
Arthralgia	107	79
Arthritis	47	36
Severe articular involvement**	6	4
Neurological Involvement	55	40
Papilloedema	29	27
Meningitis	23	26
Severe neurological involvement***	16	12
Headache morning	39	29
Hearing loss	56	42
Ophthalmologic involvement	97	71
Conjunctivitis	87	66
Uveitis	9	7
Severe ophtalmological involvement****	16	12

**Table 3: characteristics of access**

	n	%
<b>Periodic Disease</b>		
Recurrent Disease	58	42
Chronic with <del>recurrent</del> <del>access</del> exacerbations	25	18
<b>Duration of access</b>		
< 24h	27	48
1- 3 d	9	16
>3 d	20	36
<b>Number of access</b>		
<12/y	32	52
12-24/y	5	8
>24/y	24	39
<b>Fever during access</b>	83	100
<b>Fever type</b>		
>38°	48	58
<38°	35	42
<b>Trigger</b>	40	56
<b>Type of Trigger</b>		
Cold	34	85
Other*	6	15
<b>Seasonal change</b>		
Yes	20	33
No	41	67

h denotes hours, d : days ; y : years

\* : stress (n=1) ; infection (n=1) ; trauma (n=2) ; food (n=1) ; fatigue (n=2)

Commentato [HJL14]: I don't know what this means????

Formattato: Evidenziato

Formattato: Evidenziato

Formattato: Evidenziato

Formattato: Evidenziato

Formattato: Evidenziato

**Table 4: Genotype-phenotype association analysis**

Genotype/phenotype	Age onset < 6 mo	Chronic course	Relatives affected	Neurological	Severe Neurological	Articular	Severe articular	Hearing loss	Cold trigger
<b>R265W (n= 36)</b>									
yes	11 (30.6)	15 (41.7)	32 (91.4)	15 (41.7)	2 (5.6)	33 (91.7)	0 (0)	12 (33.3)	17 (47.2)
no	50 (50)	63 (63)	44 (46.3)	40 (40)	14 (14)	83 (83.8)	6 (6)	44 (44.9)	17 (17)
p		0,04	0,03	< 10-3	0,9	0,24	0,25	0,34	0,23
<b>T348M (n=20)</b>									
yes	14 (70)	17 (85)	11 (57.9)	11 (55)	0 (0)	15 (75)	0 (0)	13 (68.4)	2 (10)
no	47 (40,5)	61 (52,6)	65 (58,6)	44 (38)	16 (13,8)	101 (87,8)	6 (5,2)	43 (37,4)	32 (27,6)
p		0,01	0,007	0,96	0,15	0,13	0,16	0,59	0,01
<b>V198M (n=13)</b>									
yes	5 (38,5)	8 (61,5)	8 (66,7)	1 (7,7)	0 (0)	11 (84,6)	1 (7,7)	4 (30,8)	3 (23)
no	56 (45,5)	70 (56,9)	68 (57,6)	54 (44)	16 (13)	105 (86)	5 (4,1)	52 (43)	31 (25,2)
p		0,63	0,75	0,76	0,01	0,36	1	0,46	0,4
<b>A439V (n= 14)</b>									
yes	5 (35,7)	6 (42,9)	13 (92,9)	1 (7,1)	0 (0)	12 (85,7)	0 (0)	1 (7,1)	7 (50)
no	56 (46)	72 (59)	63 (54,3)	54 (44,3)	16 (13,1)	104 (86)	6 (4,9)	55 (45,8)	27 (22,1)
p		0,47	0,25	0,006	0,007	0,37	1	1	0,005
<b>E311K (n=9)</b>									
yes	2 (22,2)	5 (55,6)	8 (88,9)	0 (0)	0 (0)	9 (100)	0 (0)	6 (66,7)	0 (0)
no	59 (46,5)	73 (57,5)	68 (56,2)	55 (43,3)	16 (12,60)	107 (84,9)	6 (4,7)	50 (40)	34 (26,8)
p		0,19	1	0,08	0,01	0,6	0,36	1	0,16
<b>D303N (n= 5)</b>									
yes	2 (40)	2 (40)	0 (0)	4 (80)	1 (20)	5 (100)	0 (0)	3 (60)	1 (20)
no	59 (45)	76 (58)	76 (60,8)	51 (39)	15 (11,5)	111 (85,4)	6 (4,6)	53 (41,1)	33 (25,2)
p		1	0,65	0,01	0,16	0,47	1	1	0,65
<b>Q709K (n= 9)</b>									
yes	0 (0)	3 (33,3)	0 (0)	3 (33,3)	0 (0)	7 (77,8)	0 (0)	0 (0)	2 (22,2)
no	61 (100)	75 (59,1)	76 (62,3)	52 (41)	16 (12,6)	109 (86,5)	6 (4,7)	56 (44,8)	32 (25,2)
p		0,004	0,17	0,001	0,74	0,6	0,61	1	0,01
<b>No mutation (n= 3)</b>									
yes	3 (100)	3 (100)	0 (0)	3 (100)	3 (100)	3 (100)	1 (33,3)	1 (33,3)	0 (0)
no	58 (43,6)	75 (56,4)	76 (59,8)	52 (39,1)	13 (9,8)	113 (85,6)	5 (3,8)	55 (42)	34 (25,6)
p		0,09	0,26	0,07	0,06	0,001	1	0,13	0,57
<b>Rare mutations (n= 27)</b>									
yes	19 (70,4)	19 (70,4)	4 (16)	17 (63)	10 (37)	21 (80,8)	4 (14,8)	16 (61,5)	2 (7,4)
no	42 (38,5)	59 (54,1)	72 (68,6)	38 (34,9)	6 (5,5)	95 (87,2)	2 (1,9)	40 (37)	32 (29,4)
p		0,003	0,13	< 10-3	0,008	< 10-3	0,4	0,01	0,02
Total = 136 (n/%)	61 (44,85)	78 (57,35)	76 (58,46)	55 (40,44)	16 (11,76)	116 (85,93)	6 (4,41)	56 (41,79)	34 (25)

**Commentato [HJL15]:** I think this would be much easier to understand with just the positive number and percentage (the no and percentage is extremely confusing and doesn't contribute much to understanding the phenotype associated with each mutation)

Patients bearing the mutation of interest were compared to the other patients of the cohort in regards to their status for 9 clinical variables, using a chi-squared or Fisher test, according to the effectiveness. A p value of 0,01 or less was considered significant.

Figure 1

a.




Figure 1

b.





Figure 2



**Supplem. Table 1: Characteristics of patients with rare variant of *NLRP3***

Age onset: median in years (IQ25-75)	0,9	(0-0,7)
Duration of follow up: median in years (IQ25-75)	13	(5-16)
	n	%
Mode of inheritance		
AD	4	15
<i>De novo</i>	21	78
NK	2	7
Disease Pattern		
Recurrent	8	30
Chronic with access	11	40
Chronic	8	30
Age at onset < 6 month	19	70
Fever	19	70
<del>Constitutionnal</del> <u>Constitutional</u> Symptoms	22	81
Skin Involvement	27	100
Urticarial rash	24	89
Maculo-papular rash	9	33
Articular Involvement	21	78
Arthritis	9	33
Severe articular involvement	4	15
Neurological Involvement	17	63
Severe Neurological Involvement	10	37
Hearing loss	16	59
<del>Ophthalmological</del> <u>Ophthalmological</u> involvement	20	74
<del>Conjunctivitis</del> <u>Conjunctivitis</u>	10	37
Uveitis	5	19
Severe <del>ophthalmological</del> <u>ophthalmological</u> Involvement	10	37
Cold trigger	2	7

Formattato: Tipo di carattere: Corsivo

